Ownership Summary
A total of 6 institutions have reported a stake in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) as of December 2025, according to recent 13F filings with the SEC.
- China SXT Pharmaceuticals saw its institutional ownership percentage fell to 828.1% in December 2025 from 1119.7% in September 2025.
- Quarterly data indicates a 118.09% shift in institutional share volume, and the annual owner count reflects an increase of 50.00%.
- Among the 6 institutional holders of China SXT Pharmaceuticals, 4 added to their stakes while 1 trimmed their positions and 1 held steady.
- The total number of shares held by institutions in China SXT Pharmaceuticals increased to 229.89K as of December 2025, a net change of up by 124.48K shares quarter on quarter, and up 219.50K shares year over year.
- With 150.58K shares, CITADEL ADVISORS LLC commands the largest institutional position in China SXT Pharmaceuticals as of December 31, 2025, equating to 542.38% of the company.
- Among the most significant buyers of China SXT Pharmaceuticals during December 2025 were CITADEL ADVISORS LLC (101.82K), XTX Topco Ltd (22.77K), ROYAL BANK OF CANADA (818), UBS Group AG (122).
- Leading sellers of China SXT Pharmaceuticals stock in December 2025 included Tower Research Capital LLC (TRC) (1.05K).
- The top 6 institutional holders of China SXT Pharmaceuticals for the quarter ending December 2025 included CITADEL ADVISORS LLC (150.58K), GEODE CAPITAL MANAGEMENT, LLC (53.67K), XTX Topco Ltd (22.77K), Tower Research Capital LLC (TRC) (1.83K), ROYAL BANK OF CANADA (818), UBS Group AG (222).